Vaccitech plc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Vtp-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient transaminitis.

Trial will evaluate ab-729, an rnai therapy in combination with vtp-300, an immunotherapeutic, and na therapy trial will evaluate ab-729, an rnai therapy in combination with vtp-300, an immunotherapeutic, and na therapy

Revenue sharing arrangement with university of oxford could deliver further payments to vaccitech arising from milestones and royalties revenue sharing arrangement with university of oxford could deliver further payments to vaccitech arising from milestones and royalties

Oxford, united kingdom, march 25, 2022 (globe newswire) -- vaccitech plc (nasdaq: vacc) today announced its financial results for the full year ended december 31, 2021 and provided an overview of the company's recent corporate developments. vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer.

Oxford, united kingdom, jan. 18, 2022 (globe newswire) -- cancer research uk, vaccitech plc (nasdaq: vacc) and the ludwig institute for cancer research (ludwig), today announce the first patient dosed in the mage trial, which is testing a novel immunotherapeutic, vtp-600, in patients with the most common type of lung cancer.

Vaccitech plc (NASDAQ: VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies. In the VTP-.

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022. The conference will be held both in person in Miami and virtually.

Vaccitech (NASDAQ: VACC) is known to be the spin-off from Oxford University behind AstraZeneca Sars-Cov-2 vaccine.

OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.

The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Vaccitech PLC Sponsored ADR (VACC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Vaccitech plc (NASDAQ: VACC) has announced an interim analysis of safety and efficacy data of VTP-300 from the HBV002 study, including a review of surface antigen (HBsAg) levels in chronic Hepatitis B patients. Data from an interim analysis of immunogenicity and safety in Groups 1 and 2 were recently reported at the 2021 AASLD The Liver Meeting.

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy. The Phase 2a trial will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of Arbutus's AB-729, followed by Vaccitech's VTP-300, in NrtI-suppressed subjects.

Vaccitech is the company behind the COVID-19 vaccine that was developed in partnership with Oxford University for AstraZeneca. The company has several other vaccine candidates for Hepatitis B, HPV, herpes, and cancer.

OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Company's recent corporate developments.